Key facts
- Nurami’s last known valuation is $61.4M (Jun 2025).
- It has raised $43.7M; the latest was Later Stage VC ($30.0M) in Jun 2025.
- Notable investors include European Innovation Council, MedTech Innovator, Innovation Authority, Matter (Consulting Services (B2B)), Arieli Group — 16 tracked in total.
- Status: Privately Held (backing).
Investors
16+- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Nurami
- ·The full record, as it builds
Funding rounds
No funding rounds for Nurami are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nurami
Developer of biomaterials and nanofiber-based matrix designed to improve patient outcomes in various surgical procedures. The company's matrices combine porous scaffold for tissue regeneration enhancement with a novel temperature-sensitive sealant to prevent the entry of pathogens and CSF leaks, enabling surgeons to answer the unmet needs of their patients.
- Sector
- Healthcare
- HQ
- Haifa, Israel
- Founded
- 2014
- Employees
- 28
- Website
- nurami-medical.com/
- Ownership
- Privately Held (backing)
Nurami doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nurami shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nurami in its N-PORT filings yet. We sweep new filings monthly.